Your browser doesn't support javascript.
Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.
Kang, Chun-Min; Lee, Nan-Yao; Lin, Chih-Hsueh; Hsu, Yuan-Shan; Chang, Yu-Chang; Chung, Ming-Yi; Lee, Ya-Fan; Tseng, Wen-Pin; Wu, Jhong-Lin; Chen, Shey-Ying; Lu, Min-Chi; Ko, Wen-Chien; Lee, Ping-Ing; Hsueh, Po-Ren.
  • Kang CM; Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan,; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Lee NY; Department of Medicine, College of Medicine, National Cheng Kung University; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Lin CH; Division of family medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • Hsu YS; Nursing Department, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • Chang YC; Department of Laboratory Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • Chung MY; Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Lee YF; Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Tseng WP; Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Wu JL; Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Chen SY; Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Center for Quality Management, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan,. Electronic address: erdrcsy@gma
  • Lu MC; Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung, Taiwan; Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan. Electronic address: luminchi@hotmail.com.
  • Ko WC; Department of Medicine, College of Medicine, National Cheng Kung University; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: winston3415@gmail.com.
  • Lee PI; Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: pinging@ntu.edu.tw.
  • Hsueh PR; Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan,; Department of Laboratory Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Department of Internal Medicine, National Taiwan
J Clin Virol ; 150-151: 105156, 2022 06.
Article in English | MEDLINE | ID: covidwho-1773461
ABSTRACT

BACKGROUND:

In Taiwan, the vaccination program started in March 2021, with ChAdOx1-S being the first available WHO-approved COVID-19 vaccine, followed by Moderna vaccine. This study aimed to investigate the immunogenicity and safety of homologous and heterologous prime-boost regimens with ChAdOx1-S and mRNA-1273.

METHODS:

From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants. Serum samples were collected at designated time points. The anti-RBD/S1 antibody titers and neutralizing ability were measured by three different immunoassays Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Mannheim, Germany), AdviseDx SARS-CoV-2 IgG II (Abbott Diagnostics Division, Sligo, Ireland), and cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript, New Jersey, USA).

RESULTS:

We found that heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p < 0.0001), yet lower anti-RBD/S1 IgG titer (p < 0.0001) and neutralizing ability (p = 0.0101) than mRNA-1273/mRNA-1273 group. Both regimens showed higher antibody titers and superior neutralizing abilities than ChAdOx1-S/ChAdOx1-S. An age-dependent antibody response to ChAdOx1-S/mRNA-1273 was shown after both the priming and the booster doses. Younger age was associated with higher antibody production and neutralizing ability.

CONCLUSIONS:

Heterologous ChAdOx1-S/mRNA-1273 vaccination regimen is generally safe and induces a robust humoral immune response that is non-inferior to that of mRNA-1273/mRNA-1273.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunogenicity, Vaccine / COVID-19 / 2019-nCoV Vaccine mRNA-1273 / ChAdOx1 nCoV-19 Topics: Vaccines Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: J Clin Virol Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: J.jcv.2022.105156

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunogenicity, Vaccine / COVID-19 / 2019-nCoV Vaccine mRNA-1273 / ChAdOx1 nCoV-19 Topics: Vaccines Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: J Clin Virol Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: J.jcv.2022.105156